CSI Market
Sign In | Register

Verona Pharma Plc (VRNA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VRNA Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Verona Pharma Plc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2025)
6 Months 		(Mar 31 2025) (Dec 31 2024) (Sep 30 2024) (Jun 30 2024)
Operating Activities
Income11.92
Depreciation & amortization0.59
Amortization of Other Assets1.35
Accretion Expense1.65
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation34.81
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction1.10
Operating Lease Impairment Loss-
Increase Decrease In Tax And Tax Credit Receivables Current1.87
Increase Decrease In Operating Lease Liabilities-0.42
Increase Decrease In Equity Interest Receivable-
Income taxes-9.45
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-51.36
Increase (Decrease) in Accounts Payable-7.83
Increase (Decrease) in Accrued Liabilities27.11
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-3.86
Other Working Capital-3.06
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-10.61
Discontinued operations0.00
Net Cash flow from Operating Activities19.00
Investing Activities
Capital Expenditures0.54
Sale of Capital Items0.00
Proceeds from Sale of Held-to-maturity Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-1.07
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.54
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings122.50
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock10.11
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-623.89
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents399.76
Proceeds From Revenue Interest Purchase And Sale Agreement R I P S A-
Repurchase Of Revenue Interest Purchase And Sale Agreement R I P S A109.92
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities18.40
Effect of exchange rate on cash flow1.39
Discontinued operations0.00
Free Cash Flow19.54
Total Cash Flow38.26
4 historic quarters locked

Sign in to unlock the full Verona Pharma Plc cash flow history.

Sign In Create Free Account

About Verona Pharma Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001657312-25-000026

Figures are derived from filed reports and may be restated. Historical data is subject to revision.